Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4226
LifeMD
LFMD
$167M
| $208K | ﹤0.01% |
61,028
+7,300
| +14% | +$35.4K |
|
4227
Omega Flex
OFLX
$291M
| $208K | ﹤0.01% |
7,060
+882
| +14% | +$25.2K |
|
4228
ECB Bancorp
ECBK
$182M
| $207K | ﹤0.01% |
11,921
+1,076
| +10% | +$17.9K |
|
4229
Amplify Energy
AMPY
$200M
| $207K | ﹤0.01% |
+45,298
| New | +$225K |
|
4230
Senseonics Holdings Inc
SENS
$409M
| $207K | ﹤0.01% |
+37,500
| New | +$261K |
|
4231
Taylor Devices
TAYD
$170M
| $207K | ﹤0.01% |
3,533
+3,043
| +621% | +$148K |
|
|
FINV
4232
FinVolution Group
FINV
$1.07B
| $206K | ﹤0.01% |
39,416
+33,919
| +617% | +$199K |
|
4233
Duos Technologies
DUOT
$294M
| $205K | ﹤0.01% |
18,241
+16,455
| +921% | +$154K |
|
|
ACR
4234
ACRES Commercial Realty
ACR
$101M
| $205K | ﹤0.01% |
9,610
+939
| +11% | +$20K |
|
4235
Greenwich LifeSciences
GLSI
$240M
| $205K | ﹤0.01% |
9,744
+1,030
| +12% | +$10.8K |
|
|
NOAH
4236
Noah Holdings
NOAH
$591M
| $204K | ﹤0.01% |
20,306
-13,042
| -39% | -$142K |
|
4237
M-tron Industries
MPTI
$365M
| $204K | ﹤0.01% |
3,830
+317
| +9% | +$16.7K |
|
4238
Expensify
EXFY
$202M
| $203K | ﹤0.01% |
134,689
+9,080
| +7% | +$14.4K |
|
4239
Protalix BioTherapeutics
PLX
$190M
| $203K | ﹤0.01% |
112,849
+11,051
| +11% | +$22.6K |
|
4240
Union Bankshares
UNB
$122M
| $203K | ﹤0.01% |
8,542
+2,548
| +43% | +$60K |
|
4241
Grayscale Bitcoin Trust
GBTC
$9.51B
| $202K | ﹤0.01% |
+2,950
| New | +$231K |
|
|
COE
4242
51Talk Online Education Group
COE
$124M
| $201K | ﹤0.01% |
6,308
| – | – |
|
4243
Zevia
ZVIA
$101M
| $201K | ﹤0.01% |
86,775
+33,473
| +63% | +$83.1K |
|
4244
Innovator US Equity Power Buffer ETF August
PAUG
$938M
| $201K | ﹤0.01% |
+4,653
| New | +$199K |
|
4245
FT Vest US Equity Buffer & Premium Income ETF March
XIMR
$29.9M
| $201K | ﹤0.01% |
6,452
+46
| +0.7% | +$1.43K |
|
4246
Inseego
INSG
$77.7M
| $201K | ﹤0.01% |
19,593
+2,080
| +12% | +$27K |
|
4247
FT Vest US Equity Moderate Buffer ETF March
GMAR
$397M
| $200K | ﹤0.01% |
4,895
-104
| -2% | -$4.2K |
|
4248
Townsquare Media
TSQ
$104M
| $200K | ﹤0.01% |
38,955
-2,013
| -5% | -$11.3K |
|
4249
FT Vest US Equity Deep Buffer ETF February
DFEB
$464M
| $200K | ﹤0.01% |
4,195
-117
| -3% | -$5.5K |
|
4250
FT Vest US Equity Moderate Buffer ETF May
GMAY
$544M
| $200K | ﹤0.01% |
4,848
-120
| -2% | -$4.89K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.